Business Context and Reporting Period
Company: Geron Corporation
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: June 30, 1999
Business Overview: Geron is a biopharmaceutical company focused on discovering and developing therapeutic and diagnostic products for cancer and age-related degenerative diseases. Key technologies include telomerase inhibitors, stem cell therapies, and nuclear transfer. The reporting period was significantly impacted by the acquisition of Roslin Bio-Med Ltd. on May 4, 1999, and a new research collaboration with the Roslin Institute.
Key Financial Metrics
| Metric (in thousands) | Three Months Ended June 30, 1999 |
Six Months Ended June 30, 1999 |
Six Months Ended June 30, 1998 |
|---|---|---|---|
| Total Revenues | $1,346 | $2,841 | $3,761 |
| Operating Expenses | $29,342 | $34,710 | $9,254 |
| (Includes $23.4M acquired research expense) | |||
| Net Loss | $(28,000) | $(31,343) | $(4,292) |
| Net Loss Per Share (Basic/Diluted) | $(1.87) | $(2.19) | $(0.39) |
| Cash and Cash Equivalents | $19,419 | $19,419 | $6,662 |
| Total Investments (Short & Long Term) | $19,717 | $19,717 | $N/A |
| Convertible Debentures Outstanding | $9,559 | $9,559 | $6,801 |
| Accrued Research Funding Commitment | $16,323 | $16,323 | $0 |
Note: Operating expenses for the six months ended June 30, 1999, include a one-time charge of $23.4 million for acquired research technology related to the Roslin Bio-Med acquisition.
Material Changes vs. Prior Period
- Revenue Decline: Total revenues decreased 24.5% for the six months ended June 30, 1999, compared to the prior year. This was primarily due to the expiration of the Kyowa Hakko collaborative agreement in April 1998, which previously contributed significant research support payments.
- Significant Increase in Expenses: Operating expenses surged from $9.3 million in the prior year period to $34.7 million. The primary driver was the $23.4 million charge for acquired research technology (nuclear transfer license) from the Roslin Bio-Med acquisition. Excluding this charge, R&D and G&A expenses increased due to expanded operations and the integration of the UK subsidiary.
- Liquidity Position: Cash and cash equivalents increased to $19.4 million from $6.7 million in the prior year period, bolstered by the issuance of $7.5 million in Series B convertible debentures and cash acquired from Roslin Bio-Med, offset by the redemption of preferred stock and acquisition costs.
- Debt Structure: The company issued $7.5 million in Series B convertible debentures in June 1999. Additionally, the company redeemed all remaining Series A Convertible Preferred Stock ($3.7 million) during the quarter.
Guidance, Outlook, and Risks
- Capital Resources: Management estimates that existing capital, collaborative payments (Pharmacia & Upjohn), interest income, and equipment financing will fund operations through the end of 2000. However, the company anticipates needing substantial additional capital in future periods.
- Future Expenses: Operating losses are expected to continue and potentially increase due to the $20 million research funding commitment to the Roslin Institute over six years and the expansion of R&D programs.
- Key Risks:
- Product Development: All product programs are in early stages; there is no assurance of commercial viability or regulatory approval.
- Acquisition Integration: Risks associated with assimilating Roslin Bio-Med, including operational disruptions and unanticipated costs.
- Collaborative Dependence: Reliance on partners (Pharmacia & Upjohn, Kyowa Hakko, Roche) for funding, clinical trials, and commercialization.
- Intellectual Property: Uncertainty regarding patent protection and potential infringement claims.
- Year 2000 Compliance: Estimated project cost of $200,000; management believes systems will be compliant by Q3 1999, but risks of disruption remain.
Investor Verification Checklist
- Acquisition Accounting: Verify the allocation of the $44.4 million purchase price for Roslin Bio-Med, specifically the $23.4 million expensed as acquired research versus the $17.2 million capitalized as an intangible asset.
- Debt Conversion Terms: Review the terms of the Series A and Series B convertible debentures ($10.00 conversion price) and the associated warrants to assess potential future dilution.
- Research Commitments: Confirm the schedule and funding requirements for the $20 million commitment to the Roslin Institute over the next six years.
- Collaborative Revenue: Monitor the status of the Pharmacia & Upjohn agreement, which provides $1.25 million per quarter until January 2000, as a primary revenue source.
- Year 2000 Status: Verify the completion of Y2K remediation and testing, particularly for critical laboratory and financial systems, as scheduled for Q3 1999.